title: Older anti-TNF-α agents: why not group them for common indications in the EU?
authors.affiliation: a Centre for Health Economics, IRCCS, Mario Negri Institute for Pharmacological Research , Ranica , Italy.
authors.forename: Livio
authors.initials: L
authors.lastname: Garattini
authors.affiliation: a Centre for Health Economics, IRCCS, Mario Negri Institute for Pharmacological Research , Ranica , Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Ghislandi
authors.affiliation: a Centre for Health Economics, IRCCS, Mario Negri Institute for Pharmacological Research , Ranica , Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Padula
mesh_terms: D000068879:Adalimumab / Q000191:economics / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use; D000068800:Etanercept / Q000191:economics / Q000627:therapeutic use*; D005062:European Union; D006801:Humans; D000069285:Infliximab / Q000191:economics / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
keywords: anti-TNF-α; biosimilars; economic evaluation; psoriasis; rheumatoid arthritis